MYGN - ミリアド・ジェネティックス （Myriad Genetics Inc.） ミリアド・ジェネティックスMYGNのチャート
MYGNの企業情報
| symbol | MYGN |
|---|---|
| 会社名 | Myriad Genetics Inc. （ミリアド・ジェネティックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Biotechnology: In Vitro_In Vivo Diagnostic Substances |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 ミリアド・ジェネティクス（Myriad Genetics Inc.）は分子診断会社である。同社は形質転換的分子診断検査の発見、開発、販売に従事する。同社は、診断およびその他の2つの区分を通じて事業を行う。診断セグメントは病気を発症するリスクを評価し、薬物療法に応答する患者の可能性を特定し、最適な治療を可能にするために患者の投薬を導き、患者のリスクを評価するためのテストの共同開発を提供する。その他のセグメントは、医薬品、バイオテクノロジー、医療研究業界、研究開発および患者の臨床サービスに試験製品およびサービスを提供し、金融、人材、法律および情報技術などの企業サービスも含む。その分子診断検査には、myRisk遺伝性がん、BRACAnalysis CDxおよびCOLARISが含まれる。 ミリアド・ジェネティックスは、米国のバイオ医薬品企業。P4医療に焦点を置いた医薬品と分子診断製品を扱う。主要製品は遺伝性乳がんと卵巣がんの易罹患性の遺伝子検査｢BRACAnalysis｣、結腸直がんと子宮がんの遺伝子検査｢Colaris｣、メラノ―マ遺伝子検査｢Melaris｣、遺伝性膵臓がん発症予測検査｢PANEXIA｣など。 myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com. |
| 本社所在地 | 320 Wakara Way Salt Lake City UT 84108 USA |
| 代表者氏名 | John T. Henderson ジョン・T・ヘンダーソン |
| 代表者役職名 | Independent Chairman of the Board |
| 電話番号 | +1 801-584-3600 |
| 設立年月日 | 33359 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1995年 |
| 従業員数 | 2400人 |
| url | www.myriad.com |
| nasdaq_url | https://www.nasdaq.com/symbol/mygn |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 172.90000 |
| 終値（lastsale） | 43.02 |
| 時価総額（marketcap） | 3050993629.08 |
| 時価総額 | 時価総額（百万ドル） 3264.328 |
| 売上高 | 売上高（百万ドル） 772.60000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 393.028 |
| 当期純利益 | 当期純利益（百万ドル） 96.70000 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 30 June 2018 Myriad Genetics Inc. revenues increased less than 1% to $772.6M. Net income before extraordinary items increased from $21.8M to $99.1M. Revenues reflect Other segment increase of 8% to $53.3M also reflect Diagnostics segment decrease of less than 1% to $719.3M. Net income benefited from Other segment loss decrease of 74% to $20.7M Diagnostics segment income increase of 8% to $139.4M. |
MYGNのテクニカル分析
MYGNのニュース
Goldman Sachs Maintains Myriad Genetics Buy Recommendation 2023/05/25 02:37:35 24/7 Wall street
Goldman Sachs has maintained coverage of Myriad Genetics with a Buy recommendation.
Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer 2023/05/24 20:05:00 GlobeNewswire
Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE ®
Myriad Genetics Adds Folate Receptor Alpha to Precise Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer 2023/05/24 20:05:00 Wallstreet:Online
Biomarker offers another companion diagnostic option to establish eligibility for FDA-approved drug ELAHERE SALT LAKE CITY, May 24, 2023 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the addition of Folate Receptor Alpha (FRα) to its Precise Oncology Solutions portfolio. The new biomarker adds another companion diagnostic
Goldman Sachs Upgrades Myriad Genetics 2023/05/24 02:29:04 24/7 Wall street
Goldman Sachs has upgraded its outlook for Myriad Genetics to Buy.
Myriad Genetics rises as Goldman upgrades on growth potential 2023/05/23 19:43:42 Seeking Alpha
Myriad Genetics (MYGN) jumped ~13% Tuesday after Goldman Sachs upgraded it to Buy from Sell, citing its growth potential and outlook for gross margins. Read more here.
Investing in Myriad Genetics Inc. (MYGN) might be a great opportunity, but the stock is a bit overvalued 2022/11/30 12:08:00 US Post News
Myriad Genetics Inc. (NASDAQ:MYGN) closed Tuesday at $19.17 per share, up from $18.85 a day earlier. While Myriad Genetics Inc. has overperformed by 1.70%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MYGN fell by -29.13%, with highs and lows ranging from $28.45 to $15.38, whereas […]
Investing in Myriad Genetics Inc. (MYGN) might be an excellent idea, but the stock is currently overvalued/undervalued 2022/11/17 16:00:00 US Post News
Myriad Genetics Inc. (NASDAQ:MYGN) marked $19.96 per share on Wednesday, down from a previous closing price of $20.88. While Myriad Genetics Inc. has underperformed by -4.41%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MYGN fell by -33.20%, with highs and lows ranging from $30.29 to […]
Myriad Genetics Focuses on Expanding Access, Collaboration and Equity in Genetic Testing at National Society of Genetic Counselors Meeting 2022/11/14 13:00:00 GlobeNewswire
SALT LAKE CITY, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will spotlight efforts to expand access to prenatal and hereditary cancer genetic insights at the 41 st Annual National Society of Genetic Counselors (NSGC) meeting, Nov. 16-19 in Nashville, Tenn.
Myriad Genetics Announces UroSuite™, an Industry-First Suite of Genetic Tests for Prostate Cancer, Giving Urologists Access to Timely, Data-driven Medical Information 2022/11/10 13:00:00 GlobeNewswire
SALT LAKE CITY, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the launch of UroSuite, a comprehensive suite of genetic risk assessment tests that cover every stage of prostate cancer care.
Why Shares of Myriad Genetics Dropped 24% This Week 2022/11/04 01:51:00 The Motley Fool
The genetic-testing company announced an acquisition and lowered its guidance.
Myriad Genetics, Inc. (MYGN) Q3 2022 - Earnings Call Transcript 2022/11/02 01:41:06 Seeking Alpha
Myriad Genetics, Inc. (NASDAQ:NASDAQ:MYGN) Q3 2022 Earnings Conference Call November 01, 2022, 04:30 PM ET Company Participants Matthew Scalo - SVP, Investor Relations Paul Diaz - CEO,…
Myriad Genetics, Inc. 2022 Q3 - Results - Earnings Call Presentation (NASDAQ:MYGN) 2022/11/02 01:40:54 Seeking Alpha
The following slide deck was published by Myriad Genetics, Inc.
Myriad Genetics falls 19% after lowering full-year guidance, Q3 misses (NASDAQ:MYGN) 2022/11/01 15:52:16 Seeking Alpha
Myriad Genetics (MYGN) is down 19% in Tuesday morning trading after it narrowed its 2022 full-year guidance and its Q3 2022 financial results missed on the top and bottom lines.
Myriad Genetics Acquires Gateway Genomics as Q3 Revenues Drop 7 Percent, Miss Estimates 2022/11/01 14:51:05 GenomeWeb
The company reported $156.4 million in Q3 revenues compared to $167.3 million last year, and acquired consumer genetics firm Gateway Genomics.
Myriad Genetics Slashes FY22 Outlook As Q3 Results Miss Estimates; Stock Down 8% 2022/11/01 14:15:00 Finanz Nachrichten
WASHINGTON (dpa-AFX) - While reporting financial results for the third quarter on Tuesday, genetic testing firm Myriad Genetics, Inc. (MYGN) slashed its earnings and adjusted earnings and revenue …